These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24842158)

  • 21. Proteasome inhibitors induce AMPK activation via CaMKKβ in human breast cancer cells.
    Deshmukh RR; Dou QP
    Breast Cancer Res Treat; 2015 Aug; 153(1):79-88. PubMed ID: 26227473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
    Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
    Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
    Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
    Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
    Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
    Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D; Xie Y
    Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells.
    Chen MB; Zhang Y; Wei MX; Shen W; Wu XY; Yao C; Lu PH
    Cell Signal; 2013 Oct; 25(10):1993-2002. PubMed ID: 23712032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of autophagy enhances synergistic effects of Salidroside and anti-tumor agents against colorectal cancer.
    Li H; Chen C
    BMC Complement Altern Med; 2017 Dec; 17(1):538. PubMed ID: 29246220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. α-Mangostin, a dietary xanthone, induces autophagic cell death by activating the AMP-activated protein kinase pathway in glioblastoma cells.
    Chao AC; Hsu YL; Liu CK; Kuo PL
    J Agric Food Chem; 2011 Mar; 59(5):2086-96. PubMed ID: 21314123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
    Yao F; Wang G; Wei W; Tu Y; Tong H; Sun S
    Mol Med Rep; 2012 Jan; 5(1):84-8. PubMed ID: 21931937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
    Wu G; Li H; Ji Z; Jiang X; Lei Y; Sun M
    Biotechnol Lett; 2014 Jun; 36(6):1171-8. PubMed ID: 24563301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of autophagy on multiple myeloma cell viability.
    Hoang B; Benavides A; Shi Y; Frost P; Lichtenstein A
    Mol Cancer Ther; 2009 Jul; 8(7):1974-84. PubMed ID: 19509276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells.
    Xu Z; Hang J; Hu J; Gao B
    J BUON; 2014; 19(2):466-73. PubMed ID: 24965408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
    Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways.
    Bejaoui M; Zaouali MA; Folch-Puy E; Pantazi E; Bardag-Gorce F; Carbonell T; Oliva J; Rimola A; Abdennebi HB; Roselló-Catafau J
    J Pharm Pharmacol; 2014 Jan; 66(1):62-72. PubMed ID: 24127984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
    Guo Q; Chen Y; Wu Y
    Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.